Effects of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine supplementation on the body composition and muscle strength in the elderly

Saka, Bülent; Şahin, Sevnaz; Kılıç, Diclehan; Öztürk, Levent; Yılmaz, Hasan; Doğanay, Mutlu; Türkyılmaz, Serdar; Menteş, Selahattin; Usluer, Ozan; Arikan, Kursat; Çomoğlu, Selçuk; Güngör, Levent; Ziyade, Sedat; Kanat, Özkan; Seker, Duray; Canoler, Ozgur; Gözke, Eren; Akın, Sibel; Sücüllü, İlker; Tufan, Fatih

doi:10.5152/clinscinutr.2019.892

Cited by 2 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the RCT showed no beneficial effect of the intervention in the experimental arm alone, patients who received the HMB/Arg/Gln supplement had a smaller decrease in handgrip strength compared with controls 47 . All NRSIs reported a beneficial effect of HMB supplementation on increasing muscle function at follow‐up 50,51,58 . In summary, HMB showed some effects on muscle function in RCT and NRSIs.…”

Section: Resultsmentioning

confidence: 83%

“…Of these, three described the method used to assess adherence, which included self‐reported consumption of supplement through the use of logging and sheets 49,50,56 . Adherence to the study protocol ranged from 83.0% to 93.8% in RCTs 46,55,56 and from 91.4% to 98.2% in NRSIs 48,51,59 . Poor palatability or refusal to consume the experimental supplement was described in two studies using HMB/Arg/Gln 46,48 and one study providing patients with a combination of HMB/Arg/Gln and HMB‐enriched ONS 59 …”

Section: Resultsmentioning

confidence: 99%

“…47 All NRSIs reported a beneficial effect of HMB supplementation on increasing muscle function at followup. 50,51,58 In summary, HMB showed some effects on muscle function in RCT and NRSIs.…”

Section: Additional Outcomesmentioning

confidence: 90%

“…A beneficial effect of HMB supplementation on muscle mass was found in three of four RCTs 44,55,56 compared with the control group; five studies (one RCT 44 and four NRSIs 50,51,53,58 ) found a beneficial effect within the experimental arm alone. Furthermore, prevalence of low muscle mass did not change in patients receiving an HMB-enriched ONS in one RCT, 56 although there was an increase in the incidence of low muscle mass in the control group (between groups: P = 0.01).…”

Section: Primary Outcomesmentioning

confidence: 95%

“…51,55 No serious adverse events related to the nutrition intervention were recorded in three studies. 51,57,59 Despite not separating data for each clinical condition, the safety data from de Luis et al 57 was included in this analysis as no patients presented with serious adverse events. Importantly, supplementing the diet with 3.0 g/day of Ca-HMB was safe and well tolerated for over 24 weeks.…”

Section: Safetymentioning

confidence: 98%

See 4 more Smart Citations

Effects of β‐hydroxy β‐methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review

Prado

Orsso

Pereira

et al. 2022

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Low muscle mass is prevalent among patients with cancer and a predictor of adverse clinical outcomes. To counteract muscle loss, β-hydroxy β-methylbutyrate (HMB) supplementation has been proposed as a potential therapy for older adults and various diseases states. This systematic review aimed to investigate the effects and safety of HMB supplementation in relation to muscle mass and function and other clinical outcomes in patients with cancer. A systematic search of MEDLINE, CINAHL, Embase, Cochrane Central Register of Controlled Trials, Scopus, ProQuest, and grey literature for reports published from inception to December 2021 was conducted. Included studies provided supplements containing any dose of HMB to adult patients with active cancer. A synthesis without meta-analysis was conducted using a vote-counting approach based solely on the direction of the effect (i.e. regardless of statistical significance). Risk of bias was assessed for each outcome domain, and evidence from higher-quality studies (i.e. those with either low or moderate risk of bias) was examined. Safety was evaluated using both lower-quality and higher-quality studies. Fifteen studies were included, in which six were randomized controlled trials in patients with various cancer types and treatments. Studies prescribed HMB combined with amino acids (73.3%), HMB in oral nutritional supplements (20.0%), or both supplement types (6.7%); Ca-HMB doses of 3.0 g/day were provided in 80.0% of the studies. Four studies had high risk of bias across all outcome domains. Considering the higher-quality studies, evidence of a beneficial effect of HMB supplementation was found in four of four studies for muscle mass, two of two for muscle function, three of three for hospitalization, and five of seven for survival. In contrast, no beneficial effects of HMB on quality of life or body weight was found in two of four and three of five studies, respectively. A limited number of higher-quality studies evaluating the impact of HMB on cancer therapy-related toxicity, inflammation, and tumour response were observed. No serious adverse effects directly related to the nutrition intervention were reported. Although limited, current evidence suggests that HMB supplementation has a beneficial effect on muscle mass and function in patients with cancer. Well-designed trials are needed to further explore the clinical benefit of HMB supplementation in this patient population.

show abstract

Section: Resultsmentioning

confidence: 83%